{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T12:52:59Z","timestamp":1781527979325,"version":"3.54.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.clbc.2026.04.006","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T05:05:44Z","timestamp":1776143144000},"page":"44-51","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Taxane-Induced Peripheral Neuropathy\u2013Driven Treatment Modification and Pathologic Complete Response After Neoadjuvant TCHP in HER2-Positive Breast Cancer: A Retrospective Cohort Study"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-6980-9417","authenticated-orcid":false,"given":"R\u0103zvan Adrian","family":"Negreanu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolae","family":"Verga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8332-0503","authenticated-orcid":false,"given":"Estera","family":"G\u0103inariu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.clbc.2026.04.006_bib0001","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","article-title":"Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer","volume":"353","author":"Romond","year":"2005","journal-title":"N Engl J Med"},{"issue":"9938","key":"10.1016\/j.clbc.2026.04.006_bib0002","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.clbc.2026.04.006_bib0003","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clbc.2026.04.006_bib0004","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","article-title":"Neoadjuvant pertuzumab and trastuzumab in HER2-positive breast cancer (NeoSphere)","volume":"13","author":"Gianni","year":"2012","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.clbc.2026.04.006_bib0005","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1093\/annonc\/mdt182","article-title":"Pertuzumab plus trastuzumab with neoadjuvant chemotherapy regimens in HER2-positive early breast cancer (TRYPHAENA)","volume":"24","author":"Schneeweiss","year":"2013","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.clbc.2026.04.006_bib0006","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S1470-2045(18)30570-9","article-title":"Neoadjuvant chemotherapy with or without anthracyclines with dual HER2 blockade (TRAIN-2)","volume":"19","author":"van Ramshorst","year":"2018","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.clbc.2026.04.006_bib0007","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","article-title":"Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"35","author":"Loibl","year":"2024","journal-title":"Ann Oncol"},{"issue":"36","key":"10.1016\/j.clbc.2026.04.006_bib0008","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC position paper on cancer treatments and cardiovascular toxicity","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur Heart J"},{"issue":"12","key":"10.1016\/j.clbc.2026.04.006_bib0009","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.pain.2014.09.020","article-title":"Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis","volume":"155","author":"Seretny","year":"2014","journal-title":"Pain"},{"issue":"6","key":"10.1016\/j.clbc.2026.04.006_bib0010","first-page":"419","article-title":"Chemotherapy-induced peripheral neurotoxicity: a critical analysis","volume":"63","author":"Park","year":"2013","journal-title":"CA Cancer J Clin"},{"issue":"28","key":"10.1016\/j.clbc.2026.04.006_bib0011","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1200\/JCO.20.01399","article-title":"Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update","volume":"38","author":"Loprinzi","year":"2020","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.clbc.2026.04.006_bib0012","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1001\/jamaoncol.2021.1371","article-title":"Three-year follow-up of TRAIN-2","volume":"7","author":"van der Voort","year":"2021","journal-title":"JAMA Oncol"},{"issue":"34","key":"10.1016\/j.clbc.2026.04.006_bib0013","doi-asserted-by":"crossref","first-page":"5381","DOI":"10.1200\/JCO.2006.06.5391","article-title":"Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer","volume":"24","author":"Jones","year":"2006","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.clbc.2026.04.006_bib0014","first-page":"711","article-title":"Changing paradigms in neoadjuvant breast cancer therapy","volume":"17","author":"Pusztai","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"10.1016\/j.clbc.2026.04.006_bib0015","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1124\/pr.56.2.6","article-title":"Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity","volume":"56","author":"Minotti","year":"2004","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.clbc.2026.04.006_bib0016","first-page":"g4539","article-title":"How to use a subgroup analysis: users\u2019 guide to the medical literature","volume":"349","author":"Sun","year":"2014","journal-title":"BMJ"},{"issue":"10","key":"10.1016\/j.clbc.2026.04.006_bib0017","first-page":"2929","article-title":"Is pathologic complete response sufficient to omit axillary surgery in patients with breast cancer?","volume":"25","author":"Moo","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"25","key":"10.1016\/j.clbc.2026.04.006_bib0018","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1056\/NEJM200006223422507","article-title":"Randomized, controlled trials, observational studies, and the hierarchy of research designs","volume":"342","author":"Concato","year":"2000","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.clbc.2026.04.006_bib0019","doi-asserted-by":"crossref","first-page":"dju244","DOI":"10.1093\/jnci\/dju244","article-title":"Development of the National Cancer Institute\u2019s patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)","volume":"106","author":"Basch","year":"2014","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.clbc.2026.04.006_bib0020","first-page":"557","article-title":"Disease-free survival as an endpoint in neoadjuvant breast cancer trials","volume":"34","author":"Geyer","year":"2016","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clbc.2026.04.006_bib0021","first-page":"436","article-title":"NCCN Clinical Practice Guidelines in oncology: breast cancer","volume":"22","author":"Gradishar","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"10","key":"10.1016\/j.clbc.2026.04.006_bib0022","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.annonc.2021.06.023","article-title":"Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021","volume":"32","author":"Burstein","year":"2021","journal-title":"Ann Oncol"},{"issue":"26","key":"10.1016\/j.clbc.2026.04.006_bib0023","first-page":"2697","article-title":"The neoadjuvant model is still the future for drug development in breast cancer","volume":"33","author":"DeMichele","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2026.04.006_bib0024","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s10549-020-05866-1","article-title":"Real-world effectiveness of dual HER2 blockade with pertuzumab and trastuzumab for neoadjuvant treatment of HER2-positive early breast cancer (the NEOPETRA Study)","volume":"184","author":"Gonz\u00e1lez-Santiago","year":"2020","journal-title":"Breast Cancer Res Treat"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820926000583?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820926000583?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T12:02:06Z","timestamp":1781524926000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820926000583"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1526820926000583"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2026.04.006","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Taxane-Induced Peripheral Neuropathy\u2013Driven Treatment Modification and Pathologic Complete Response After Neoadjuvant TCHP in HER2-Positive Breast Cancer: A Retrospective Cohort Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2026.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}